ACCELERO: Ph3 Study to evaluate PF-08046054 vs Docetaxel in PD-L1+ NSCLC
Phase III Clinical Trial
A RANDOMIZED PHASE 3 OPEN-LABEL STUDY TO EVALUATE PF-08046054/SGN-PDL1V VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY-TREATED PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC) - Protocol C5851005
Participating Locations